05:04 PM EDT, 06/05/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Wednesday that VTX3232 effectively reduced body weight and food intake during two preclinical diet-induced obesity mouse model studies.

The results show that the drug decreased liver steatosis and triglycerides, and also had greater benefits in combination with semaglutide, according to the company.

The company said it plans to start a phase 2a study in patients with obesity and other cardiovascular risk factors during H2.

Company shares were down nearly 4% in recent after-hours activity.

Price: 5.08, Change: -0.20, Percent Change: -3.79